CFTR Suppresses Neointimal Formation Through Attenuating Proliferation and Migration of Aortic Smooth Muscle Cells

Liu-Yi Lu1, Ni Pan1, Ze-Han Huang2

  • 1Institute of Pediatrics, Guangzhou Women and Children's Medical Centre, Guangzhou Medical University, Guangzhou, China.

Insights

Cystic fibrosis transmembrane conductance regulator (CFTR) attenuates neointimal formation by inhibiting vascular smooth muscle cell proliferation and migration. CFTR suppresses key signaling pathways activated by platelet-derived growth factor-BB (PDGF-BB).

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Vascular Remodeling

Background:

  • Cystic fibrosis transmembrane conductance regulator (CFTR) is crucial for arterial function and cellular fate.
  • Understanding CFTR's role in vascular remodeling, particularly in response to growth factors and injury, is essential.

Purpose of the Study:

  • To investigate whether CFTR directly regulates platelet-derived growth factor-BB (PDGF-BB)-stimulated vascular smooth muscle cell (VSMC) proliferation and migration.
  • To determine CFTR's effect on neointimal formation following balloon injury in a rat carotid artery model.

Main Methods:

  • Adenoviral gene delivery of CFTR in a rat carotid artery balloon injury model.
  • Assessment of VSMC proliferation and migration using mitochondrial tetrazolium assay, wound healing assay, and transwell chamber method.
  • Analysis of signaling pathways and gene expression via western blot and quantitative PCR (qPCR).

Main Results:

  • CFTR expression decreased in injured rat carotid arteries.
  • Overexpression of CFTR attenuated neointimal formation and inhibited PDGF-BB-induced VSMC proliferation and migration.
  • CFTR silencing showed opposite effects, and CFTR suppressed PDGF-BB-induced phosphorylation of PDGF receptor β, SGK1, JNK, p38, and ERK, as well as MMP2/9 expression.

Conclusions:

  • CFTR plays a significant role in regulating VSMC behavior and vascular remodeling.
  • CFTR attenuates neointimal formation by suppressing PDGF-BB-induced activation of SGK1 and the JNK/p38/ERK signaling pathway.